RET
14 drugsRearranged During Transfection Proto-Oncogene
Predictive biomarker for patient selection in 32 indications
Understanding RET
What it means: RET alterations include fusions (lung cancer) and point mutations (thyroid cancer). Drives cancer through constitutive kinase activity.
Why it matters: Selective RET inhibitors selpercatinib and pralsetinib show high response rates in RET-altered cancers.
Testing: Tested via NGS for fusions and mutations. FISH can detect rearrangements but misses mutations.
14
Approved Drugs
32
Indications
12
Companies
RET is a precision-medicine biomarker linked to 14 FDA-approved targeted drugs from 12 companies, spanning 32 indications including Metastatic colorectal cancer, Locally advanced, unresectable or metastatic gastrointestinal stromal tumor, Hepatocellular carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing RET drugs below.
Search RET Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting RET
| Drug | Company | Therapeutic Area |
|---|---|---|
| ALECENSA | Roche | Oncology |
| CABOMETYX | EXELIXIS | Oncology |
| CAPRELSA | Sanofi | Oncology |
| COMETRIQ | EXELIXIS | Oncology |
| GAVRETO | RIGEL PHARMS | Oncology |
| ICLUSIG | Takeda | Oncology |
| LENVIMA | EISAI INC | Oncology |
| NEXAVAR | Bayer | Oncology |
| RESNIBEN | AZURITY | Oncology |
| RETEVMO | Eli Lilly | Oncology |
| SORAFENIB TOSYLATE | YABAO PHARM | Oncology |
| STIVARGA | Bayer | Oncology |
| SUNITINIB MALATE | Dr. Reddy's | Oncology |
| SUTENT | CPPI CV | Oncology |
RET Indications
Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Gastrointestinal Stromal Tumor Renal Cell Carcinoma Pancreatic Neuroendocrine Tumor Gastrointestinal stromal tumor (GIST) Advanced renal cell carcinoma (RCC) Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomy Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) Hepatocellular Carcinoma Thyroid Carcinoma Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Advanced renal cell carcinoma Hepatocellular carcinoma previously treated with sorafenib Locally advanced or metastatic differentiated thyroid cancer Well-differentiated pancreatic neuroendocrine tumors Well-differentiated extra-pancreatic neuroendocrine tumors Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Advanced renal cell carcinoma (first-line, in combination with pembrolizumab) Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus) Unresectable hepatocellular carcinoma (first-line) Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab) Medullary Thyroid Cancer Non-Small Cell Lung Cancer Thyroid Cancer Solid Tumors Unresectable hepatocellular carcinoma Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment